ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: While the chronic phase of CML is dependent on BCR–ABL1, progression to acute blast crisis is mediated by additional genetic alterations, and murine models of this disease progression are necessary to develop therapies for this patient subset who are unresponsive the tyrosine kinase inhibitors (46).